AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Zura Bio Limited Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Zura Bio Limited furnished a press release announcing its second quarter 2025 financial results and attached that press release as Exhibit 99.1 to this Form 8-K. The filing states the results disclosure is furnished under Item 2.02 rather than "filed," and the press release itself is incorporated by reference into the exhibit list.

The company also confirms its securities trading symbol and that it qualifies as an emerging growth company. No financial tables, specific revenue, earnings or other numeric results are included within the 8-K text; interested readers must refer to Exhibit 99.1 for the full press release content.

Zura Bio Limited ha fornito un comunicato stampa che annuncia i risultati finanziari del secondo trimestre 2025 e ha allegato tale comunicato come Exhibit 99.1 a questo Form 8-K. Il deposito specifica che la divulgazione dei risultati è stata effettuata come "furnished" ai sensi dell'Item 2.02 e non come "filed", e il comunicato è incorporato per riferimento nell'elenco degli exhibit.

L'azienda conferma inoltre il proprio simbolo di negoziazione e la qualifica come società in fase di crescita. Nel testo dell'8-K non sono incluse tabelle finanziarie, dati specifici su ricavi, utili o altri risultati numerici; i lettori interessati devono consultare l'Exhibit 99.1 per il contenuto completo del comunicato.

Zura Bio Limited presentó un comunicado de prensa que anuncia sus resultados financieros del segundo trimestre de 2025 y adjuntó ese comunicado como Exhibit 99.1 en este Form 8-K. La presentación indica que la divulgación de los resultados se realizó como "furnished" bajo el Item 2.02 y no como "filed", y el comunicado se incorpora por referencia en la lista de exhibits.

La compañía también confirma su símbolo de negociación y que califica como empresa emergente en fase de crecimiento. En el texto del 8-K no se incluyen tablas financieras, cifras concretas de ingresos, ganancias u otros resultados numéricos; los interesados deben remitirse al Exhibit 99.1 para el comunicado completo.

Zura Bio LimitedëŠ� 2025ë…� 2분기 재무 ê²°ê³¼ë¥� 발표하는 ë³´ë„ìžë£Œë¥� 제출했으ë©�, 해당 ë³´ë„ìžë£Œë¥� ì� Form 8-Kì� Exhibit 99.1ë¡� 첨부했습니다. 제출서ì—ëŠ� ê²°ê³¼ 공시가 "filed"ê°€ 아닌 항목 2.02ì—� 따른 "furnished"ë¡� ì´ë£¨ì–´ì¡Œë‹¤ê³  명시ë˜ì–´ 있으ë©�, ë³´ë„ìžë£Œ ìžì²´ëŠ� exhibit 목ë¡ì—� 참고ë¡� í¬í•¨ë˜ì–´ 있습니다.

회사ëŠ� ë˜í•œ ìžì‚¬ ì¦ê¶Œì� 거래 기호와 ìžì‹ ì� ì‹ í¥ ì„±ìž¥ 기업으로 ìžê²©ì� 있ìŒì� 확ì¸í•©ë‹ˆë‹�. 8-K 본문ì—는 재무í‘�, 특정 매출·ì´ìµ ë˜ëŠ” 기타 수치 결과가 í¬í•¨ë˜ì–´ 있지 않으므ë¡�, ìžì„¸í•� ë³´ë„ìžë£Œ ë‚´ìš©ì€ Exhibit 99.1ì� 참조해야 합니ë‹�.

Zura Bio Limited a transmis un communiqué de presse annonçant ses résultats financiers du deuxième trimestre 2025 et a joint ce communiqué en tant que Exhibit 99.1 à ce Form 8-K. Le dépôt précise que la divulgation des résultats a été fournie en tant que « furnished » en vertu de l'Item 2.02 et non « filed », et le communiqué est incorporé par référence à la liste des exhibits.

La société confirme également son symbole de cotation et qu'elle remplit les conditions pour être une entreprise en phase de croissance. Le texte du 8-K ne contient pas de tableaux financiers, ni de chiffres précis de revenus, bénéfices ou autres résultats numériques ; les lecteurs intéressés doivent se référer à l'Exhibit 99.1 pour le communiqué complet.

Zura Bio Limited hat eine Pressemitteilung veröffentlicht, in der die Finanzergebnisse für das zweite Quartal 2025 angekündigt werden, und diese Pressemitteilung als Exhibit 99.1 diesem Form 8-K beigefügt. Die Einreichung weist darauf hin, dass die Ergebnisangabe unter Punkt 2.02 als "furnished" und nicht als "filed" erfolgt ist, und die Pressemitteilung selbst ist als Verweis in die Exhibit‑Liste aufgenommen.

Das Unternehmen bestätigt zudem sein Börsenkürzel und dass es den Status einer emerging growth company besitzt. Im Text des 8-K sind keine Finanztabellen, konkreten Umsatzzahlen, Gewinne oder andere numerische Ergebnisse enthalten; Interessierte müssen Exhibit 99.1 für den vollständigen Pressemitteilungstext heranziehen.

Positive
  • Press release furnished as Exhibit 99.1, ensuring public distribution of the company's second quarter 2025 results
  • Disclosure of emerging growth company status, which is explicitly indicated in the filing
Negative
  • No financial figures or tables included in the 8-K text; readers must open Exhibit 99.1 for numeric results
  • Item 2.02 information is furnished, not "filed", which affects legal incorporation into future filings

Insights

TL;DR: Routine earnings disclosure furnished as an exhibit; no material new financial detail in the Form 8-K itself.

The company furnished a press release reporting quarterly financial results but included no numeric metrics within the 8-K text. As a result, this filing serves primarily as a vehicle to distribute the press release and does not on its own change the financial record. Investors should consult Exhibit 99.1 for the actual figures; until those figures are reviewed, the 8-K is informational and not a material standalone disclosure.

TL;DR: Governance disclosure is procedural—the registrant furnished earnings information and explicitly noted it is not being "filed" under the Exchange Act.

The Form 8-K follows standard practice of furnishing a press release under Item 2.02 and listing it as Exhibit 99.1. The statement that the Item 2.02 content is not "filed" is important for legal incorporation considerations. The filing confirms the company’s emerging growth company status, which may affect reporting transitions, but otherwise contains no governance actions or executive changes.

Zura Bio Limited ha fornito un comunicato stampa che annuncia i risultati finanziari del secondo trimestre 2025 e ha allegato tale comunicato come Exhibit 99.1 a questo Form 8-K. Il deposito specifica che la divulgazione dei risultati è stata effettuata come "furnished" ai sensi dell'Item 2.02 e non come "filed", e il comunicato è incorporato per riferimento nell'elenco degli exhibit.

L'azienda conferma inoltre il proprio simbolo di negoziazione e la qualifica come società in fase di crescita. Nel testo dell'8-K non sono incluse tabelle finanziarie, dati specifici su ricavi, utili o altri risultati numerici; i lettori interessati devono consultare l'Exhibit 99.1 per il contenuto completo del comunicato.

Zura Bio Limited presentó un comunicado de prensa que anuncia sus resultados financieros del segundo trimestre de 2025 y adjuntó ese comunicado como Exhibit 99.1 en este Form 8-K. La presentación indica que la divulgación de los resultados se realizó como "furnished" bajo el Item 2.02 y no como "filed", y el comunicado se incorpora por referencia en la lista de exhibits.

La compañía también confirma su símbolo de negociación y que califica como empresa emergente en fase de crecimiento. En el texto del 8-K no se incluyen tablas financieras, cifras concretas de ingresos, ganancias u otros resultados numéricos; los interesados deben remitirse al Exhibit 99.1 para el comunicado completo.

Zura Bio LimitedëŠ� 2025ë…� 2분기 재무 ê²°ê³¼ë¥� 발표하는 ë³´ë„ìžë£Œë¥� 제출했으ë©�, 해당 ë³´ë„ìžë£Œë¥� ì� Form 8-Kì� Exhibit 99.1ë¡� 첨부했습니다. 제출서ì—ëŠ� ê²°ê³¼ 공시가 "filed"ê°€ 아닌 항목 2.02ì—� 따른 "furnished"ë¡� ì´ë£¨ì–´ì¡Œë‹¤ê³  명시ë˜ì–´ 있으ë©�, ë³´ë„ìžë£Œ ìžì²´ëŠ� exhibit 목ë¡ì—� 참고ë¡� í¬í•¨ë˜ì–´ 있습니다.

회사ëŠ� ë˜í•œ ìžì‚¬ ì¦ê¶Œì� 거래 기호와 ìžì‹ ì� ì‹ í¥ ì„±ìž¥ 기업으로 ìžê²©ì� 있ìŒì� 확ì¸í•©ë‹ˆë‹�. 8-K 본문ì—는 재무í‘�, 특정 매출·ì´ìµ ë˜ëŠ” 기타 수치 결과가 í¬í•¨ë˜ì–´ 있지 않으므ë¡�, ìžì„¸í•� ë³´ë„ìžë£Œ ë‚´ìš©ì€ Exhibit 99.1ì� 참조해야 합니ë‹�.

Zura Bio Limited a transmis un communiqué de presse annonçant ses résultats financiers du deuxième trimestre 2025 et a joint ce communiqué en tant que Exhibit 99.1 à ce Form 8-K. Le dépôt précise que la divulgation des résultats a été fournie en tant que « furnished » en vertu de l'Item 2.02 et non « filed », et le communiqué est incorporé par référence à la liste des exhibits.

La société confirme également son symbole de cotation et qu'elle remplit les conditions pour être une entreprise en phase de croissance. Le texte du 8-K ne contient pas de tableaux financiers, ni de chiffres précis de revenus, bénéfices ou autres résultats numériques ; les lecteurs intéressés doivent se référer à l'Exhibit 99.1 pour le communiqué complet.

Zura Bio Limited hat eine Pressemitteilung veröffentlicht, in der die Finanzergebnisse für das zweite Quartal 2025 angekündigt werden, und diese Pressemitteilung als Exhibit 99.1 diesem Form 8-K beigefügt. Die Einreichung weist darauf hin, dass die Ergebnisangabe unter Punkt 2.02 als "furnished" und nicht als "filed" erfolgt ist, und die Pressemitteilung selbst ist als Verweis in die Exhibit‑Liste aufgenommen.

Das Unternehmen bestätigt zudem sein Börsenkürzel und dass es den Status einer emerging growth company besitzt. Im Text des 8-K sind keine Finanztabellen, konkreten Umsatzzahlen, Gewinne oder andere numerische Ergebnisse enthalten; Interessierte müssen Exhibit 99.1 für den vollständigen Pressemitteilungstext heranziehen.

false 0001855644 0001855644 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 8-K

 

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

August 14, 2025

Date of Report (Date of earliest event reported)

 

 

 

Zura Bio Limited

(Exact name of registrant as specified in its charter)

 

Cayman Islands   001-40598   98-1725736
(State or other jurisdiction of
incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

1489 W. Warm Springs Rd. #110

Henderson, NV 89014

(Address of principal executive offices,

including zip code)

 

(702) 825-9872

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Ordinary Shares, par value $0.0001 per share   ZURA   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 14, 2025, Zura Bio Limited (“ZURA”, the “Company”) issued a press release announcing its second quarter 2025 financial results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

 

The information in this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit
No.
  Description
99.1   Press Release dated August 14, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ZURA BIO LIMITED
   
Date: August 14, 2025 By: /s/ Kim Davis
    Kim Davis
    Chief Operating Officer, Chief Legal Officer and Corporate Secretary

 

 

 

 

FAQ

What did Zura Bio (ZURA) disclose in this Form 8-K?

ZURA furnished a press release announcing its second quarter 2025 financial results, included as Exhibit 99.1.

Is the Item 2.02 information in the 8-K considered "filed"?

No. The company states the Item 2.02 information is furnished and should not be deemed "filed" under the Exchange Act.

Where can I find the actual financial results referenced by ZURA?

The financial results are in the press release attached as Exhibit 99.1 to the Form 8-K.

Did the 8-K include financial statements or tables?

No. The filing contains no financial statements or numeric tables; only the press release exhibit is provided.

Does Zura Bio identify as an emerging growth company in the filing?

Yes, the registrant indicated it is an emerging growth company.
Zura Bio Limited

NASDAQ:ZURA

ZURA Rankings

ZURA Latest News

ZURA Latest SEC Filings

ZURA Stock Data

87.24M
43.83M
29.16%
70.82%
0.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
LA JOLLA